Over this main effect, GLP-1 and its agonists can reduce the glucagon secretion, slow the gastric transit and decrease the energy consumption extending the effects on treatment of obesity. The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.